The Pharmacy Compounding Advisory Committee is the federal advisory body that reviews substances nominated for the 503A bulks list and makes recommendations to FDA on whether they should be permanently listed, sent to the do-not-compound list, or kept under evaluation
Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market
Muscle injury recovery pathway research
The effect of meniscal tears on cartilage loss of the knee: findings on serial MRIs
Until, and if, it returns to shelves, have a read of this blog to learn about the current data on its benefits to see how it may help with longevity